Cariprazine Publications 2006-2020

Non-clinical

Chemistry
Physico-chemical characterization of a novel group of dopamine D3/D2 receptor ligands, potential atypical antipsychotic agents
Deák K, Takács-Novák K, Kapás M, Vastag M, Tihanyi K, Noszál B

Discovery of cariprazine (RGH-188): A novel antipsychotic acting on dopamine D3/D2 receptors

Discovery of cariprazine (chemical aspects) (published in Hungarian) Open access
Domány Gy
Magyar Kémikusok Lapja 71: 261-262; 2016

The chemistry that lead to cariprazine (published in Hungarian with English abstract) Open access
Domány Gy, Greiner I
Magyar Kémiai Folyóirat 122: 112-116; 2016

Neurochemistry
Cariprazine (RGH-188), a dopamine D3 receptor preferring D3/D2 dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile
J Pharmacol Exp Ther 333: 328-340; 2010

Occupancy of dopamine D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography
Psychopharmacology 218: 579-587; 2011

In vitro and in vivo comparison of [3H](+)-PHNO and [3H]-raclopride binding to rat striatum and lobes 9 and 10 of the cerebellum: A method to distinguish dopamine D3 from D2 receptor sites
Kiss B, Horti F, Bobok A
Synapse 65: 467-478; 2011

Synapse 67: 258-264; 2013

Long-Term Effects of Cariprazine Exposure on Dopamine Receptor Subtypes
Choi YK, Adham N, Kiss B, Gyertyán I, Tarazi FI
CNS Spectrums 19: 268-277; 2014
Long-term effects of aripiprazole exposure on monoaminergic and glutamatergic receptor subtypes: comparison with cariprazine. Open access
Choi YK, Adham N, Kiss B, Gyertyán I, Tarazi FI
CNS Spectrums, 22: 484-494; 2017

Effects of cariprazine on extracellular levels of glutamate, GABA, dopamine, noradrenaline and serotonin in the medial prefrontal cortex in the rat phencyclidine model of schizophrenia studied by microdialysis and simultaneous recordings of locomotor activity. Open access
Kehr J, Yoshitake T, Ichinose F, Yoshitake S, Kiss B, Gyertyán I, Adham N
Psychopharmacology 235: 1593–1607; 2018

Involvement of 5-HT1A and 5-HT2A receptors but not α2-adrenoceptors in the acute electrophysiological effects of cariprazine in the rat brain in vivo. Open access
Herman A, El Mansari M, Adham N, Kiss B, Farkas B, Blier P
Mol Pharmacol 94: 1363-1370; 2018

The role of dopamine D3 receptor partial agonism in cariprazine-induced neurotransmitter efflux in rat hippocampus and nucleus accumbens
Huang M, He W, Kiss B, Farkas B, Adham N, Meltzer HY
J Pharm Exp Ther 371: 517-525; 2019

Long-term administration of cariprazine increases locus coeruleus noradrenergic neurons activity and serotonin1A receptor neurotransmission in the hippocampus
J Psychopharmacol 1-12; 2020; doi: 10.1177/0269881120936891

Pharmacology
RGH-188, a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and pro-cognitive effects in rodents
Neurochemistry International 59: 925-935; 2011

Cariprazine, a dopamine D3-receptor-prefering partial agonist, block phencyclidine-induced impairments of working memory, attention set shifting, and recognition memory in the mouse.
Zimnisky R, Chang G, Gyertyán I, Kiss B, Adham N, Schmauss C
Psychopharmacology 226: 91-100; 2013

Cariprazine (RGH-188), a D3-preferring dopamine D3/D2 receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in rats
Román V, Gyertyán I, Sághy K, Kiss B, Szombathelyi Z
Psychopharmacology 226: 285-293; 2013

Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression
Papp M, Gruca P, Lason-Tyburkiewicz M, Adham N, Kiss B, Gyertyán I
Behav Pharmacol 25: 567-574; 2014

Cariprazine exerts antimanic properties and interferes with dopamine D2 receptor β-arrestin interactions. Open access
Gao Y, Peterson S, Masri B, Hougland MT, Adham N, Gyertyán I, Kiss B, Caron MG and El-Mallakh RS
Pharma Res Per 3: e00073, 1-10; 2014
Cariprazine delays ouabain-evoked epileptiform spikes and loss of activity in rat hippocampal slices
El-Mallakh RS, Payne RS, Schurr A, Gao Y, Lei Z, Kiss B, Gyertyán I, Adham N
Psychiatry Res 229: 370-373; 2015

Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology
Neill JC, Grayson B, Kiss B, Gyertyán I, Ferguson P, Adham N
Eur Neuropsychopharmacol 26: 3-14; 2016

The dopamine D3-prefering D2/D3 dopamine receptor partial agonist, cariprazine, reverses behavioral changes in a rat neuro-developmental model for schizophrenia
Watson DJG, King MV, Gyertyán I, Kiss B, Adham N, Fone KC
Eur Neuropsychopharmacol 26: 208-224; 2016

Cariprazine exhibits anxiolytic and dopamine D3 receptor-dependent antidepressant effects in the chronic stress model
Duric V, Banasr M, Franklin T, Lepack A, Adham N, Kiss B, Gyertyán I, Duman RS
Int J Neuropsychopharmacol 20: 788-796; 2017

The effects of cariprazine and aripiprazole on PCP-induced deficits on attention assessed in the 5-choice serial reaction time task
Barnes S, Young J, Markou A, Adham N, Gyertyán I, Kiss B
Psychopharmacology 235: 1403-1414; 2018

The novel atypical antipsychotic cariprazine demonstrates dopamine D2 receptor-dependent partial agonist actions on rat mesencephalic dopamine neuronal activity
Delcourte S, Ashby CR, Rovera R, Kiss B, Adham N, Farkas B, Haddjeri N
CNS Neurosci. Ther. 24: 1129-1139; 2018

Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine
Drug Des Develop Ther 13: 3229-3248; 2019

The novel antipsychotic cariprazine stabilizes gamma oscillations in rat hippocampal slices
Meier MA, Lemercier CE, Kulisch C, Kiss B, Lendvai B, Adham N, Gerevich Z
Br J Pharmacol 1-13; 2020; doi: 10.1111/bph.14923

Pharmacokinetic
Sensitive LC-MS/MS methods for the quantification of RGH-188 and its active metabolites, desmethyl- and didesmethyl-RGH-188 in human plasma and urine
Pásztor Mészáros G, Ágai-Csongor É, Kapás M

Clinical
Schizophrenia
An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial. Open access
Schizopr Res 152: 450-457; 2014

Cariprazine in acute exacerbation of schizophrenia: A fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. Open access
J Clin Psychiatry 76: e1574-e1582; 2015

Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: Results from an international, phase III clinical trial. Open access

Cariprazine in the treatment of schizophrenia: A proof-of-concept trial. Open access
Int Clin Psychopharmacol 31: 61-68; 2016

Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial. Open access
Durgam S, Earley W, Li R, Li D, Lu K, Laszlovszky I, Fleischhacker WW, Nasrallah HA
Schizopr Res 176: 264-271; 2016

The effect of cariprazine on hostility associated with schizophrenia. Open access
Citrome L, Durgam S, Lu K, Ferguson P, Laszlovszky I

Cariprazine as monotherapy for the treatment of predominant negative symptoms in patients with schizophrenia: A randomized, double-blind, active-comparator controlled trial. Open access at Richter website
Lancet 389: 1103-1113; 2017

Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study. Open access
CNS Spectrums 23: 39-50; 2018

Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: Results from a 48-week, open-label extension study. Open access
Durgam S, Greenberg WM, Li D, Lu K, Laszlovszky I, Németh G, Migliore R, Volk S
Psychopharmacology 234: 199-209; 2017

Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies. Open access
Earley W, Durgam S, Lu K, Laszlovszky I, Debelle M, Kane JM
Int Clin Psychopharmacol 32: 319-328; 2017
The safety and tolerability of cariprazine in long-term treatment of schizophrenia: A post hoc pooled analysis

BMC Psychiatry 17: 305; 2017

Negative Symptoms of Schizophrenia: Constructs, Burden, and Management

Barabássy A, Szatmári B, Laszlovzky I, Németh G
Psychotic Disorders: An Update; Edited by Federico Durbano, IntechOpen, pp. 43-62; 2018
ISBN 978-953-51-5976-6; http://dx.doi.org/10.5772/intechopen.73300

Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data

Schizophr Res 204: 282-288; 2019

Long-term remission with cariprazine treatment in patients with schizophrenia: A post hoc analysis of a randomized, double-blind, placebo-controlled, relapse prevention trial

Correll CU, Potkin SG, Zhong Y, Harsányi J, Szatmári B, Earley W
J Clin Psychiatry 80: 18m12495; 2019

Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies

Eur Neuropsychopharmacol 29: 127-136; 2019

The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors

Eur Psychiatry 58: 1-9; 2019

Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: Understanding negative symptom scores in schizophrenia

Neuropsychopharmacol 44: 1589-1596; 2019

Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation

Correll CU, Jain R, Meyer JM, Periclou A, Carrothers T, Barabássy Á, Patel M, Earley W
Neuropsychiatr Dis Treat 15: 2537–2550; 2019

Cariprazine safety in adolescents and the elderly: Analyses of clinical study data

Szatmári B, Barabássy Á, Harsányi J, Laszlovzky I, Sebe B, Gál M, Shiragami K, Németh G
Front Psychiatry 11: article 61 (1-11); 2020

Cariprazine therapy in the spirit of functionality – new ways in schizophrenia treatment (Published in Hungarian with English abstract)

Laszlovzky I, Barabássy Á, Németh G
Cariprazine publications 2006 – 2020_v4

*Psychiat Hung* **35** (Suppl 1): 12–26; 2020

**Mania**

The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial


*Bipolar Disord* **17**: 63-75; 2015

Cariprazine in the treatment of acute mania in bipolar I disorder: A double-blind, placebo controlled, phase III trial


*J Affect Disord* **174**: 296-302; 2015

Efficacy and safety of low- and high-dose cariprazine in patients with acute and mixed mania associated with bipolar I disorder


*J Clin Psychiatry* **76**: 284-292; 2015

Effect of cariprazine across the symptoms of mania in bipolar I disorder: Analyses of pooled data from phase II/III trials

Vieta E, Durgam S, Lu K, Ruth A, Debelle M, Zukin S

*Eur Neuropsychopharm* **25**: 1882-1891; 2015

Tolerability of cariprazine in the treatment of acute bipolar I mania: A pooled post hoc analysis of 3 phase II/III studies

Earley W, Durgam S, Lu K, Debelle M, Laszlovzky I, Vieta E, Yatham LN

*J Affect Disord* **215**: 205-212; 2017

The safety and tolerability of cariprazine in patients with bipolar I disorder: A 16-week open-label study


*J Affect Disord* **225**: 350-356; 2018

Clinically relevant response and remission outcomes in cariprazine-treated patients with bipolar I disorder


*J Affect Disord* **226**: 239-244; 2018

Cariprazine for the treatment of bipolar mania with mixed features: A post hoc pooled analysis of 3 trials

McIntyre RS, Masand PS, Earley W, Patel M

*J Affect Disord* **257**: 600-606; 2019

**Schizophrenia & Mania**

Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: a pooled post hoc analysis


*Int J Clin Pract* e13037; 2017
**Bipolar Depression**

An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression


**Cariprazine Treatment of Bipolar Depression: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study**


*Am J Psychiatry* **176**: 439–448; 2019

**Cariprazine efficacy in bipolar I depression with and without concurrent manic symptoms: post hoc analysis of 3 randomized, placebo-controlled studies**

McIntyre RS, Suppes T, Earley W, Patel M, Stahl SM

*CNS Spectrums*; 2019, [https://doi.org/10.1017/S1092852919001287](https://doi.org/10.1017/S1092852919001287)

A pooled post hoc analysis evaluating the safety and tolerability of cariprazine in bipolar depression

Earley WR, Burgess M, Rekeda L, Hankinson A, McIntyre RS, Suppes T, Calabrese JR, Yatham LN

*J Affect Disord* **263**: 386-395; 2020

**Evaluation of cariprazine in the treatment of bipolar I and II depression: a randomized, double-blind, placebo-controlled, phase 2 trial**

Yatham LN, Vieta E, Earley WR

*Int Clin Psychopharmacol* **35**: 147–156; 2020

**Broad efficacy of cariprazine on depressive symptoms in bipolar disorder and the clinical implications**

Yatham LN, Vieta E, McIntyre RS, Jain R, Patel M, Earley W

*Prim Care Companion CNS Disord* **22**: 20m02611; 2020

**Major Depression add-on**

Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: A randomized, double-blind, placebo-controlled study in adult MDD patients


**Efficacy of adjunctive low-dose cariprazine in major depressive disorder: A randomized, double-blind, placebo-controlled trial**

Fava M, Durgam S, Earley W, Lu K, Hayes R, Laszlovszy I, Németh G

*Int Clin Psychopharmacol* **33**: 312-321; 2018

**Cariprazine augmentation to antidepressant therapy in major depressive disorder: Results of a randomized, double-blind, placebo-controlled trial**

Earley W, Guo H, Németh G, Harsányi J, Thase M

*Psychopharmacology Bulletin* **48**: 62-80; 2018

**Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder**

Vieta E, Earley WR, Burgess MV, Durgam S, Chen C, Zhong Y, Barabássy Á, Németh G
**Int Clin Psychopharmacol** 34: 76-83; 2019

**Efficacy and safety of cariprazine in bipolar I depression: A double-blind, placebo-controlled phase 3 study**[Open access](#)
Earley W, Burgess MV, Khan B, Rekeda L, Suppes T, Tohen M, Calabrese JR
*Bipolar Disord* **22**:372–384; 2020

**Other Indications**

**Wernicke–Korsakoff syndrome associated with mtDNA disease**[Open access](#)
*Ther Adv Neurol Disord* **13**: 1–7; 2020

**Human Pharmacokinetic**

**Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C](+)-PHNO**[Open access](#)
*Psychopharmacology* **233**: 3503-3512; 2016

**Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment)**[Open access](#)
*Drug Design Develop Ther* **10**: 327-338; 2016

**Comment on: “Clinical Pharmacokinetics of Atypical Antipsychotics: An Update”**[Open access](#)
Periclou A, Riccobene T, Kapás M, Laszlovszky I
*Clinical Pharmacokinet* **58**: 1215-1216; 2019

**Relationship between plasma concentrations and clinical effects of cariprazine in patients with schizophrenia or bipolar mania**[Open access](#)
*Clin Transl Sci* **13**: 362–371; 2020

**Health Technology Assessment (HTA)**

**Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone**[Open access](#)
*J Comp Eff Res* **6**: 639-648; 2017

**Cost-utility analysis of cariprazine compared to risperidone among patients with negative symptoms of schizophrenia**
*Health Policy Tech* **8**: 84-91; 2019

**Population-level QALY gain estimates with the use of cariprazine for patients with negative symptoms of schizophrenia in Hungary (Published in Hungarian with English abstract)**[Open access](#)
Bendes R, Németh B, Pitter JG, Kóczíán K, Götze Á, Kaló Z
*LAM* **29**:467–475; 2019
Using informative prior based on expert opinion in Bayesian estimation of the transition probability matrix in Markov modelling—an example from the cost-effectiveness analysis of the treatment of patients with predominantly negative symptoms of schizophrenia with cariprazine

Cost Eff Resour Alloc 18:28; 2020

General

Cariprazine – a milestone of the Hungarian drug research and unique possibility for the treatment of predominant negative symptoms of patients with schizophrenia.

A new chemical entity, developed by Gedeon Richter Plc. in Hungary received market authorization approval from FDA in schizophrenia and bipolar mania indications (Published in Hungarian with English abstract)

Laszlovszky I, Németh G
Gyógyszerész 59: 643-646; 2015

In nutshell about cariprazine (Published in Hungarian)
Laszlovszky I, Barabássy Á
Psychiatric and Neurology Times – Hungarian edition, (5) 26-28, 2018

Cariprazine, a new type – dopamine D₃ receptor preferring – partial agonist atypical antipsychotic for the treatment of schizophrenia and the primary negative symptoms. (Published in Hungarian with English abstract)

Laszlovszky I, Kiss B, Barabássy Á, Kapás M, Németh G
Neuropsychopharmacol Hung 21: 103-118; 2019